Abstract
Background Evaluation of suspected coronavirus disease-2019 (COVID-19) patient is a diagnostic dilemma as it commonly presents like influenza in early stages. Studies and guidelines have emerged both for and against the use of imaging as a frontline tool to investigate such patients. Reverse transcriptase-polymerase chain reaction (RT-PCR) is suggested as the backbone of diagnosis. We designed and tested a diagnostic algorithm using artificial intelligence (AI) to determine the role of imaging in the evaluation of patients with acute flu-like presentation.
Materials and Methods Overall, 3,235 consecutive patients with flu-like presentation were evaluated over a period of 240 days. All patients underwent plain radiographs of chest with computer-aided detection for COVID-19 (CAD4COVID) AI analysis. Based on the threshold scores, they were divided into two groups: group A (score < 50) and group B (score > 50). Group A patients were discharged and put on routine symptomatic treatment and follow-up with RT-PCR, while group B patients underwent high-resolution computed tomography (HRCT) followed by COVID-19 AI analysis and RT-PCR test. These were then triaged into COVID-19 and non-COVID-19 subgroups based on COVID-19 similarity scores by AI, and lung severity scores were also determined.
Results Group A had 2,209 (68.3%) patients with CAD4COVID score of <50 while 1,026 (31.7%) patients comprised group B. Also, 825 (25.5%) patients were COVID-19 positive with COVID-19 similarity threshold of >0.85 on AI. RT-PCR was positive in 415 and false-negative in 115 patients while 12 patients died before the test could be done. The sensitivity and specificity of CAD4COVID AI analysis on plain radiographs for detection of any lung abnormality combined with HRCT AI analysis was 97.9% and 99% using the above algorithm.
Conclusion Combined use of chest radiographs and plain HRCT with AI-based analysis is useful and an accurate frontline tool to triage patients with acute flu-like symptoms in non-COVID-19 health care facilities.